Abstract 1591P
Background
Gastric cancer (GC) is 5th most common cancer and 4th most common cause of cancer death worldwide. The rate of GC in patients < 40 years in different countries is ∼ 5%. The incidence and characteristics of GC in <40 patients were not studied in Georgian population. We analyzed clinicopathologic features of early onset GC in Georgia.
Methods
In this study we analyzed data from national cancer registry of Georgia 2015-2021. The data included number of cases, age, sex, anatomic location, stage, pathology and treatment types of GC. Aim of the study was to investigate clinicopathologic characteristics, treatment approaches and survival rates of GC in patients <40 compared to entire cohort. Survival was summarized by Kaplan-Meier method.
Results
A total of 1775 patients with GC were included in the study during 2015-2021. Out of 1775 patients 52 (2,9%) were < 40 years. Median age 34 (17-39). In <40 patients 50% were female, while in entire cohort 62% were male. No differences were seen in anatomic location, tumor grade, stage. Stage III (25 % in <40 patients vs 29% in entire cohort) and IV (40% vs 43%) were most common. Differences were seen in pathologic types - not otherwise classified adenocarcinoma 31% in <40 patients vs 25% in entire cohort (P value 0.3367), not otherwise classified carcinoma 26 % vs 2% (P value <0.0001), signet ring carcinoma 17% vs 6% respectively (P value 0.0004). In entire cohort rate of undifferentiated carcinoma was 30% and tubular adenocarcinoma 16%, which were not seen in <40 patients. 23% of <40 patients vs 30% entire cohort had surgery (P value 0.2294) and 42% vs 30% chemotherapy (P value 0.0714). Median overal survival (OS) for patients <40 was 20 months (95% CI 9,0-30,0) and 13 months for entire cohort (95% CI 12,0-15,0) (p value – 0,1488).
Conclusions
This study showed, that in Georgian <40 patients GC is equally distributed between both sexes, while in the entire cohort it is slighlty more common in males. Pathologic types as not otherwise classified carcinoma and signet ring carcinoma were seen most frequently in <40 patients. <40 patients were slightly more likely to receive chemotherapy and surgery. However, median OS was <2 years for patients <40. Further studies are required to understand causes of early onset GC in Georgian patients and to improve survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
T. Esakia.
Funding
Has not received any funding.
Disclosure
E. Smyth: Financial Interests, Personal, Invited Speaker: Amgen, Bristol Myers Squibb, Imedex, Merck, Novartis, Prova Education, Servier, TouchIME, Elsevier, PeerVoice, Cor2Ed, Daiichi Sankyo; Financial Interests, Personal, Other, TSC: Amgen; Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, Bristol Myers Squibb, Bristol Myers Squibb, My Personal Therapeutics, Novartis, Roche, Servier, Zymeworks, Viracta; Financial Interests, Personal, Other, IDMC: BeiGene, Zymeworks; Financial Interests, Personal, Other, IDMC chair: Everest Clinical Research; Financial Interests, Personal, Officer: EORTC GI Clinical Trials Group; Financial Interests, Institutional, Local PI: Daiichi Sankyo, Merus, Basilea, MSD, Mirati; Financial Interests, Institutional, Coordinating PI: Roche, AstraZeneca, Amgen; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb; Non-Financial Interests, Leadership Role, Trustee: UK & Ireland Oesophagogastric Group (UKIOG). All other authors have declared no conflicts of interest.
Resources from the same session
1645P - STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)
Presenter: Himil Mahadevia
Session: Poster session 22
1646P - Genomic and prognostic differences in patients with different KRAS mutations in pancreatic cancer
Presenter: Chunwei Xu
Session: Poster session 22
1647P - Cancer-associated endocrine cell: A novel component of tumor microenvironment in pancreatic cancer
Presenter: Yuan Chen
Session: Poster session 22
1648P - Association between circulating tumor cell count and thrombosis in pancreatic cancer
Presenter: Monica Benavente
Session: Poster session 22
1649P - Comprehensive genomic profiling contributes to the prognosis of patients with advanced pancreatic cancer
Presenter: Eiichiro So
Session: Poster session 22
1650P - Identification of potential targets in pancreatic adenocarcinoma: The KRAS Wild-Type subset
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1651P - Comparison of surgical outcome and prognostic factors between pancreaticobiliary and intestinal types of periampullary adenocarcinoma following pancreaticoduodenectomy
Presenter: Saad Anwar
Session: Poster session 22
1652P - Interaction between enhanced cytokine signalling and ferroptosis defence fuels obesity-associated pancreatic ductal adenocarcinoma oncogenesis
Presenter: Rishat Ruzi
Session: Poster session 22
1653P - The activated thermogenesis of intra-pancreatic fat fuels the progression of pancreatic cancer
Presenter: Xi'n'peng Yin
Session: Poster session 22
1654P - Circulating tumor cells (CTCs) as prognostic factor for pancreatic cancer: Updated of a prospective study
Presenter: Natalia Gutierrez Alonso
Session: Poster session 22